Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Truqap
Pharma
Roche burnishes breast cancer portfolio with FDA nod for Itovebi
To be marketed under the brand name Itovebi, inavolisib is a threat to Novartis’ fellow PI3K inhibitor Piqray and AstraZeneca’s AKT inhibitor Truqap.
Angus Liu
Oct 10, 2024 5:30pm
AstraZeneca stands by Truqap despite surprise breast cancer flop
Sep 13, 2024 10:00am
AZ's Truqap came up short in triple-negative breast cancer study
Jun 18, 2024 9:09am
AZ's first-in-class breast cancer approval marred by restriction
Nov 17, 2023 11:02am
